Navigation Links
Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
Date:4/1/2008

a mechanism for those seeking regulatory approval of a drug product through a New Drug Application (NDA) to obtain formal review of any Agency decision through a Formal Dispute Resolution process by raising the matter with the supervisor of the employee who made the decision. If the issue is not resolved at the primary supervisory level, the applicant may request that the matter be reviewed at the next higher supervisory level. This process may continue through the Agency's chain of command, through the Centers to the Commissioner of Food and Drugs. The Formal Dispute Resolution process exists to encourage open, prompt discussion of scientific (including medical) disputes and procedural (including administrative) disputes that arise during the drug development, new drug review, generic drug review, and post-marketing oversight processes.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become an integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the FDA's Formal Dispute Resolution process, the outcomes of clinical trials, the regulatory process
'/>"/>

SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
2. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
3. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
4. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
5. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
6. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
7. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
8. Labopharm Reports Results for Third Quarter Fiscal 2007
9. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
10. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
11. Labopharm appeals FDAs decision on once-daily tramadol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... A quality built chicken coop condo with a wheel ... to raise chickens on a pasture. By installing a wheel ... have a chicken tractor that stands up to being moved around ... it is able to flex to uneven ground without losing its ... are fertilized, and it will help provide the chickens with fresh ...
(Date:5/6/2015)... The Canton Group is joining Lardarius Webb ... charity softball game. The event takes place on Friday, May ... years guests include Joe Flacco, John Harbaugh, Ed Reed and ... if you are interested in attending. , The Canton ... SOAR Baltimore and The CollegeBound Foundation , ...
(Date:5/6/2015)... 06, 2015 Animals make just as good ... also good for your health. An Ohio veterinarian ... increase he's seeing with health advantages of owning a pet. ... it comes to pet ownership, there are proven health benefits ... Scott Leffler of the Animal Medical Center of ...
(Date:5/6/2015)... Anitha Nallari, MD has joined ... Inc. in Columbus, OH. Dr. Nallari will see patients ... in breast cancer, lung cancer, GI and gallbladder cancer, head ... benign hematology. , Dr. Anitha Nallari is Board ... American Board of Internal Medicine. She completed her medical education ...
(Date:5/6/2015)... May 06, 2015 Anitoa Systems, (“Anitoa”), ... with Zhejiang University of China, has successfully demonstrated a ... CMOS bio-optical sensor. Anitoa’s handheld qPCR is shown ... DNA and RNA’s, including hepatitis B, C, and E. ... 4 copies per sample and over 9 orders of ...
Breaking Medicine News(10 mins):Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... NY The American Cancer Society and the National Palliative ... grants to researchers at 12 institutions for studies aimed at ... The studies will be conducted over the next two years. ... 51 grants totaling almost $7 million. These grants, which are ...
... ... first in the Albany, NY area to have Laser-Assisted Smartlipo Triplex™ technology to offer ... and faster healing times. , ... Albany-Schenectady-Troy, NY (PRWEB) May 12, 2010 -- Traditional liposuction has been available ...
... doses of metformin, Avandia cut risk by two-thirds in study, ... pre-diabetes, a low-dose combination of two diabetes drugs -- metformin ... type 2 diabetes, new research shows. , The study found ... by two-thirds in those taking the drug combo compared to ...
... between 18 and 25, researchers say , WEDNESDAY, June 2 ... what they believe -- or hope -- is true: Teenagers ... study found that as teens become young adults, many -- ... impulsive behaviors decreases, along with the amount of alcohol they ...
... be tailored to individual patients, researchers say , , WEDNESDAY, ... can benefit from deep brain stimulation in either one of ... The Veterans Affairs researchers compared two different targets in the ... and the globus pallidus interna (GPi) -- both of which ...
... very few if any, really know how likely they are ... to change, thanks to a new discovery by an international ... access people,s personal risk for skin cancer. In ... Journal ( http://www.fasebj.org ), these researchers describe for the ...
Cached Medicine News:Health News:$1.8 million awarded for palliative care research to improve care of seriously ill patients 2Health News:$1.8 million awarded for palliative care research to improve care of seriously ill patients 3Health News:$1.8 million awarded for palliative care research to improve care of seriously ill patients 4Health News:$1.8 million awarded for palliative care research to improve care of seriously ill patients 5Health News:Breakthrough In Liposuction Comes To New York's Capital District 2Health News:Drug Combo Staves Off Type 2 Diabetes 2Health News:Drug Combo Staves Off Type 2 Diabetes 3Health News:Impulsive Behavior, Drinking Decline in Early Adulthood 2Health News:Deep Brain Stimulation Works in Two Sites for Parkinson's Disease 2Health News:Deep Brain Stimulation Works in Two Sites for Parkinson's Disease 3Health News:Sun-induced skin cancer: new discovery permits doctors to assess genetic risk 2
(Date:5/6/2015)... SEATTLE, May 6, 2015  CTI BioPharma Corp. (NASDAQ ... first quarter ended March 31, 2015. ... Phase 3 clinical trial of pacritinib during the quarter, ... of treating physicians who are excited by the potential ... need in the treatment of patients with myelofibrosis, specifically ...
(Date:5/6/2015)...  Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX ) ... March 31, 2015 and provided an update on its ... make progress across our targeted oncology clinical programs," said ... CEO, Mirati. "We look forward to providing updates on ... Oncology meeting at the end of the month, and ...
(Date:5/6/2015)... 2015 Delcath Systems, Inc. (NASDAQ: DCTH ... on oncology with an emphasis on the treatment of ... the three months ended March 31, 2015.  ... include: , Achieved quarterly product revenue of $0.44 ... the first quarter of 2014; , Activated a ...
Breaking Medicine Technology:CTI BioPharma Reports First Quarter 2015 Financial Results 2CTI BioPharma Reports First Quarter 2015 Financial Results 3CTI BioPharma Reports First Quarter 2015 Financial Results 4CTI BioPharma Reports First Quarter 2015 Financial Results 5CTI BioPharma Reports First Quarter 2015 Financial Results 6CTI BioPharma Reports First Quarter 2015 Financial Results 7CTI BioPharma Reports First Quarter 2015 Financial Results 8CTI BioPharma Reports First Quarter 2015 Financial Results 9Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 2Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 3Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 4Mirati Therapeutics Reports First Quarter 2015 Financial Results and Provides Business Update 5Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8
... (CBI) Prolactin ELISA kit is used for ... serum or plasma. Human prolactin (lactogenic hormone) ... a molecular weight of approximately 23,000 daltons. ... solid phase direct sandwich ELISA method. The ...
Prolactin Radioimmunoassay...
... a polypeptide hormone secreted in significant amounts ... placenta. Prolactin, in synergy with estrogen, plays ... and maintenance of mammary gland growth and ... may have effects on cell growth in ...
... This Enzyme-Linked Immunosorbent Assay (ELISA) serves ... (RBP) from plasma, serum and,urine. In a ... the samples is bound to an,available excess ... is,immobilized to the surface of the microtitre ...
Medicine Products: